Edition:
United States

Rigel Pharmaceuticals Inc (RIGL.OQ)

RIGL.OQ on NASDAQ Stock Exchange Global Select Market

2.91USD
22 Oct 2018
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$2.91
Open
$3.01
Day's High
$3.02
Day's Low
$2.89
Volume
346,748
Avg. Vol
691,496
52-wk High
$4.71
52-wk Low
$2.56

Latest Key Developments (Source: Significant Developments)

Rigel Pharmaceuticals Q2 Loss Per Share $0.16
Wednesday, 8 Aug 2018 04:08pm EDT 

Rigel Pharmaceuticals Inc ::RIGEL ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE.Q2 LOSS PER SHARE $0.16.Q2 EARNINGS PER SHARE VIEW $-0.16 -- THOMSON REUTERS I/B/E/S.QTRLY NET PRODUCT SALES FROM TAVALISSE OF $1.8 MILLION.  Full Article

Rigel Initiates Phase 1 Clinical Trial Of R835 For Autoimmune And Inflammatory Diseases
Tuesday, 26 Jun 2018 07:30am EDT 

June 26 (Reuters) - Rigel Pharmaceuticals Inc ::RIGEL INITIATES PHASE 1 CLINICAL TRIAL OF R835, AN IRAK1/4 INHIBITOR FOR AUTOIMMUNE AND INFLAMMATORY DISEASES.RIGEL PHARMACEUTICALS INC - PHASE 1 STUDY WAS INITIATED IN Q2 OF 2018.  Full Article

Rigel Pharmaceuticals Q1 Loss Per Share $0.17
Tuesday, 1 May 2018 04:01pm EDT 

Rigel Pharmaceuticals Inc ::RIGEL ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE.Q1 LOSS PER SHARE $0.17.Q1 EARNINGS PER SHARE VIEW $-0.18 -- THOMSON REUTERS I/B/E/S.AS OF MARCH 31, HAD CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS OF $94.3 MILLION, VERSUS $115.8 MILLION AS OF DEC 31, 2017.RIGEL - EXPECTS CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS TO BE SUFFICIENT THROUGH AT LEAST NEXT 12 MONTHS.  Full Article

Rigel Pharmaceuticals Says Expects To Report About $94.3 Mln Cash, Cash Equivalents, Short-Term Investments As Of March 31, 2018
Friday, 20 Apr 2018 04:29pm EDT 

April 20 (Reuters) - Rigel Pharmaceuticals Inc ::RIGEL PHARMACEUTICALS SAYS EXPECTS TO REPORT IT HAD ABOUT $94.3 MILLION CASH, CASH EQUIVALENTS, SHORT-TERM INVESTMENTS AS OF MARCH 31, 2018 - SEC FILING.  Full Article

Rigel Announces Pricing Of Public Offering Of Common Stock
Thursday, 19 Apr 2018 07:32pm EDT 

April 19 (Reuters) - Rigel Pharmaceuticals Inc ::RIGEL ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.PUBLIC OFFERING OF 16,000,000 SHARES OF ITS COMMON STOCK, OFFERED AT A PRICE OF $3.90 PER SHARE TO PUBLIC.  Full Article

Rigel Intends To Offer & Sell Up To 15 Mln Shares Of Its Stock In Underwritten Public Offering
Wednesday, 18 Apr 2018 04:34pm EDT 

April 18 (Reuters) - Rigel Pharmaceuticals Inc ::RIGEL ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.RIGEL PHARMACEUTICALS INC - INTENDS TO OFFER & SELL UP TO 15 MILLION SHARES OF ITS STOCK IN AN UNDERWRITTEN PUBLIC OFFERING.RIGEL PHARMACEUTICALS INC - PROCEEDS FROM OFFERING TO BE USED FOR ACTIVITIES IN CONNECTION WITH COMMERCIAL LAUNCH OF TAVALISSE IN UNITED STATES.  Full Article

Rigel Pharmaceuticals NDA For Tavalisse Approved By FDA
Tuesday, 17 Apr 2018 02:02pm EDT 

April 17 (Reuters) - U.S. Food And Drug Administration::RIGEL PHARMACEUTICALS NDA FOR TAVALISSE APPROVED BY FDA.  Full Article

Rigel Makes Statement Regarding Website Error
Thursday, 12 Apr 2018 03:57pm EDT 

April 12 (Reuters) - Rigel Pharmaceuticals Inc ::RIGEL MAKES STATEMENT REGARDING WEBSITE ERROR.FDA IS CONTINUING ITS REVIEW OF NDA AND PDUFA ACTION DATE FOR FOSTAMATINIB NDA IS APRIL 17.DUE TO AN ERROR, INACCURATE INFORMATION WAS DISPLAYED REGARDING U.S. FDA'S REVIEW OF NDA FOR FOSTAMATINIB.CO'S WEBSITE HAS BEEN CORRECTED.  Full Article

Rigel Pharma Q4 Loss Per Share $0.18
Tuesday, 6 Mar 2018 04:01pm EST 

March 6 (Reuters) - Rigel Pharmaceuticals Inc ::RIGEL ANNOUNCES FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE.Q4 LOSS PER SHARE $0.18.‍THERE WERE NO CONTRACT REVENUES FROM COLLABORATIONS IN Q4 OF 2017​.  Full Article

Rigel to Provide Business Review and Updated Phase 2 Results for Fostamatinib
Thursday, 4 Jan 2018 07:30am EST 

Jan 4 (Reuters) - Rigel Pharmaceuticals Inc ::RIGEL PHARMACEUTICALS - ‍FDA HAS CONFIRMED IT DOES NOT PLAN TO CONVENE ONCOLOGY DRUGS ADVISORY COMMITTEE MEETING TO DISCUSS NDA FOR FOSTAMATINIB​.RIGEL PHARMACEUTICALS INC - ACTION DATE FOR FDA TO COMPLETE ITS REVIEW FOR FOSTAMATINIB IS APRIL 17, 2018 UNDER PDUFA.  Full Article

BRIEF-Rigel Pharmaceuticals Q1 Loss Per Share $0.17

* RIGEL ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE